SPARC and neoplasm: AKT inhibitor IV did further sensitize the cells to TMZ, and 0.25 μM AKT inhibitor IV in combination with 80 μM TMZ was able to suppress the survival of SPARC-expressing tumor cells to that observed for control cells treated with TMZ alone (Figure 4C).